Oramed completes sale of Oratech to Lifeward for shares, warrants and revenue payments
Oramed said Lifeward Ltd. completed its acquisition of Oratech Pharma, Oramed's wholly owned subsidiary, on March 25, 2026, paying with Lifeward shares, warrants and a revenue-based payment stream. The same day, Oramed closed a $9,000,000 purchase of Lifeward senior secured convertible notes, which the filing describes as previously announced terms being finalized rather than new terms.
Key points
- Lifeward issued Oramed 1,250,363 ordinary shares, 1,006,113 pre-funded warrants at $0.0001 per share, and warrants for up to 1,296,296 shares at an initial $5.40 exercise price.
- Oramed will receive revenue-based payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties, for up to 10 years or until earlier defined limits.
- Oramed bought $9,000,000 aggregate principal of Lifeward notes, convertible at an initial $5.40 per share, plus warrants for up to 1,666,666 Lifeward shares.
- Both transactions closed on March 25, 2026, under agreements dated January 12, 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.